Avtor/Urednik		Čemažar, Maja; Grošel, Alenka; Glavač, Damjan; Kotnik, Vladimir; Škoberne, Mojca; Kranjc, Simona; Mir, Lluis M; Andre, Frank; Opolon, Paule; Serša, Gregor
Naslov		Effects of electrogenetherapy with p53wt combined with cisplatin on survival of human tumor cell lines with different p53 status
Tip		članek
Vir		DNA Cell Biol
Vol. in št.		Letnik 22, št. 12
Leto izdaje		2003
Obseg		str. 765-75
Jezik		eng
Abstrakt		The aim of our study was to evaluate electrogenetherapy with p53wt alone or combined with cisplatin on two colorectal (HT-29 and LoVo) and two prostatic (PC-3 and Du145) carcinoma ccll lines with different p53 status. In addition, the feasibility of electrogenetherapy with p53wt was tested also in vivo on PC-3 prostatic cancer xenografts. Electrogenetherapy with p53wt was dependent on the p53 status of the eell lines used. Electrogenetherapy was the most effective on the PC-3 (p53 null) and Du145 (p53mt) cells, and to the much lesser extent in LuVo cells (p53wt). The exception was the HT-29 cell line with overexpressed mutated p53, where electrogenetherapy with p53wt was the least effective. Sensitivity of the cell lines to cisplatin was independent of the p53 status. Furthermore, the presence of exogenous p53 due to electrogenetherapy did not enhance cisplatin cytotoxicity, since the combinarion of these therapies resulted in additive cytotoxic effect. The effectiveness of electrogenetherapy with p53wt was also demonstrated in vivo by suceessful treatment of subcutaneous PC-3 tumors in mice. In conclusion, our study shows that electrogenetherapy with p53wt is feasible, and resulted in comparable cytotoxic and antitumor effcetiveness to viral-mediated p53wt gene therapy. This therapy was effective and dependent on the p53 status of the tumor cell lines. Combination of electrogenetherapy and cisplatin resulted in additional cell kill by cisplatin, and was not dependent on the p53 status.
Deskriptorji		COLORECTAL NEOPLASMS CISPLATIN ELECTROPORATION GENE THERAPY PROSTATIC NEOPLASMS ANTINEOPLASTIC AGENTS APOPTOSIS CELL SURVIVAL COMBINED MODALITY THERAPY GENETIC VECTORS LUMINESCENT PROTEINS MICE, NUDE PROTEIN P53 SURVIVAL ANALYSIS TRANSFECTION TUMOR CELLS, CULTURED